drugset / Trial / NCT03314402

The Tolerance, Pharmacokinetics of Jaktinib in Healthy Volunteers

NCT03314402

Phase 1 Completed 126 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blinding, dose-escalated phase 1 trial to evaluate the tolerance and fasting/postprandial pharmacokinetics of jaktinib.

Timeline

Start
2017-09-28
Primary completion
2018-08-30
Completion
2018-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Jaktinib Unknown Oral

Indications

No indication recorded.